Stryker now sees FY23 adjusted EPS of $10.35-$10.45, consensus $10.36

Stryker said: “Considering our year-to-date results, our robust backlog for capital equipment and continued positive procedural trends, we now expect full year 2023 organic net sales growth to be in the range of 10.0% to 10.5% including slightly positive pricing for the year. If foreign exchange rates hold near their current levels, we anticipate net sales will be unfavorably impacted by approximately 0.6% and adjusted net earnings per diluted share will be unfavorably impacted by $0.10 to $0.15 for the full year, both of which are included in our guidance. Based on our performance in the first nine months of the year, together with our strong sales momentum, we now expect adjusted net earnings per diluted share(2) to be in the range of $10.35 to $10.45.”